Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Tate & Lyle bulks up food ingredients with $1.8 bln CP Kelco deal



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Tate & Lyle bulks up food ingredients with $1.8 bln CP Kelco deal</title></head><body>

Tate to pay $1.15 bln in cash, rest in shares

J.M. Huber to hold 16% stake in Tate

Tate shares down more than 8%

Updates shares in paragraphs 2 and 8, adds analyst comment in paragraphs 3 and 5

By Radhika Anilkumar

June 20 (Reuters) -Britain's Tate & Lyle TATE.L has struck a $1.8 billion deal to buy U.S.-based CP Kelco to boost its speciality ingredients business and tap demand for plant-based products.

Shares dropped more than 8% after Thursday's announcement, hit by investor concern over CP Kelco performance.

"The deal looks a good fit in terms of scope and size, with a reasonable valuation multiple, although the market will want reassurance that the recent volume decline and margin pressure at CP Kelco reflects cyclical not structural factors," Barclays analysts said in a note.

Sweetener maker Tate & Lyle, which has a market capitalisation of 2.7 billion pounds ($3.4 billion) said it would pay $1.15 billion in cash and issue 75 million new Tate & Lyle shares to CP Kelco's parent company J.M. Huber Corporation.

Barclays noted that CP Kelco's profit margin has dropped about 500 basis points to 17% since 2021, making current profitability lower than its long-term average.

CP Kelco, formed in 2000 by the merger of Kelco and Copenhagen Pectin, provides pectin, speciality gums and other nature-based ingredients such as lily pads, orange peel and seaweed. It was bought by J.M. Huber in 2004.

Tate CEO Nick Hampton said the deal would help the company to meet growing consumer demand for plant-based products with sustainable ingredients and fewer artificial additives.

The company's shares, which fell as much as 8.6% by 1140 GMT, were on track for their biggest one-day fall since March 2020 and were among the biggest fallers on the pan-European STOXX 600 .STOXX index.

The proposed transaction is expected to generate cost benefits of at least $50 million by the end of the second financial year after the deal is completed, Tate added.

The deal is expected to close in the fourth quarter of 2024.

Huber will also become Tate's largest shareholder after the deal, with a stake of about 16%, and will be able to appoint two non-executive directors to the Tate board.


($1 = 0.7870 pounds)



Reporting by Radhika Anilkumar in Bengaluru
Editing by Mrigank Dhaniwala, Mark Potter and David Goodman

</body></html>

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.